Dividend DeclarationSource: RNS
BIOPHARMA CREDIT PLC
("BIOPHARMA CREDIT" OR THE "COMPANY")
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 30 June 2022 of $0.0175 per ordinary share, payable on 23 September 2022 to ordinary shareholders on the register as at 26 August 2022. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.
The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.
The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 26 August 2022 (the "Election Date").
Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST. Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.
Link Company Matters Limited
16 August 2022
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.